Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Advertising & Marketing

Sales

Legal & Regulatory

Acquisition & Integration

Goodwill impairment

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Teladoc

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. The company was founded on June 13, 2002, by George Byron Brooks and Gary Wald and is headquartered in Purchase, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teladoc reports solid Q4 growth, eyes revenue optimization strategies

Teladoc's Q4 performance showed revenue growth and margin focus, with BetterHelp contributing significantly to profitability.
The company's strategic focus on virtual care expansion and revenue optimization positions Teladoc for continued success in the healthcare market.
While facing internal restructuring challenges, Teladoc's emphasis on growth drivers and operational efficiency presents opportunities for future growth and market leadership.

Teladoc Health excels in Q1, eyes growth and efficiency

Teladoc Health's Q1 performance was strong, with revenue exceeding expectations.
The company is focused on efficiency, innovation, and driving value in virtual care.
BetterHelp segment showed growth and stability, with improving margins expected.
Opportunities exist to capitalize on ad pricing stability and consumer behavior trends.

Teladoc surpasses revenue expectations, focuses on innovation and growth

Teladoc's Q2 performance exceeded expectations, with strong revenue growth and improved margins in both segments. The company's strategic focus on whole-person care, weight management, and AI enhancements positions it well for future growth. Challenges include managing drug costs and private company valuations, while opportunities lie in virtual care demand and strategic M&A.
Teladoc's financial strength, commitment to innovation, and focus on efficiency improvements are key strengths driving its performance. The company's ability to navigate challenges and capitalize on opportunities in the evolving healthcare landscape underscores its resilience and growth potential.

Teladoc Health surpasses Q3 expectations, eyes margin expansion in '24

Teladoc Health's Q3 performance exceeded expectations, driven by revenue growth and margin improvements.
The company is focused on enhancing cost efficiencies, profitability, and driving margin expansion.
Stable pricing environment and strong client demand present opportunities for future growth.
Operational review and strategic initiatives position Teladoc for continued success in the healthcare sector.

Teladoc reports robust 2023 earnings, eyes growth amid marketing challenges

Teladoc delivered strong financial performance in 2023 with notable growth in adjusted EBITDA and revenue. The company faces challenges in BetterHelp marketing yields and delayed consumer engagement efforts.
However, Teladoc's strategic strengths lie in its long-term outlook for revenue growth, margin expansion, and cost-saving initiatives. Opportunities exist in optimizing sales force structure and capital deployment for future growth.
Overall, Teladoc's focus on profitability, growth optimization, and strategic capital allocation positions it well for sustained success in the telehealth industry.

Teladoc Health reports solid Q1 performance amidst revenue challenges

Teladoc Health's Q1 2024 performance showcased revenue growth in Integrated Care but challenges in BetterHelp segment revenue and margin management.
The company's financial strength, product portfolio, and cost initiatives position it well for growth opportunities and strategic market positioning.
Addressing challenges in ad spend management and focusing on international market efficiency are key to unlocking growth potential and improving financial performance.
Overall, Teladoc's performance, strengths, challenges, and opportunities reflect a dynamic landscape with strategic focus on sustainable growth and operational efficiency.

Teladoc Health reports Q2 revenue dip, EBITDA growth; addresses challenges

Teladoc Health's Q2 2024 performance showed mixed results with revenue decline but EBITDA growth. The company is leveraging strengths in patient safety and technology while addressing challenges in customer acquisition costs. Opportunities lie in operational efficiency, insurance coverage access, and international expansion.

Teladoc Health reports Q3 revenue decline but strategic growth

Teladoc Health's Q3 2024 performance reflects mixed results with revenue decline but strategic growth in the Integrated Care segment.
The company's focus on customer-centric strategies, technology, and clinical excellence positions it well for future success and market leadership.
Challenges in revenue decline and expense management require Teladoc Health to balance short-term financial performance with long-term growth objectives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002, by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in Purchase, NY.

This is a dedicated price action analysis of Teladoc stock. We observed that TDOC has been consolidating firmly after its post-earnings sell-off. TDOC outperformed the market since our April update, increasing its near-term support's resilience. However, we have not observed a bear trap to help reverse its bearish bias.

Teladoc: Reiterating Our Speculative Buy As It Held Firm

Abbott Labs

Pfizer

Declines in the market make now the time to go bargain hunting.

Stock Market Drop: 3 Cheap Healthcare Stocks to Buy Right Now

SAN DIEGO--(BUSINESS WIRE)---- $TDOC #TDOC--Teladoc Health, Inc. (TDOC) missed first quarter financial estimates due to a $6.6 billion non-cash goodwill impairment charge

Teladoc Health, Inc. Investor News: Robbins LLP is Investigating Teladoc Health, Inc. (TDOC)

An analyst shaves his price target on the leading telehealth company.

Why Teladoc Health Shot More Than 5% Higher Today

New York, New York--(Newsfile Corp. - June 17, 2022) - Levi & Korsinsky, LLP notifies investors in Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC) of a class action securities lawsuit.The lawsuit on behalf of Teladoc investors has been commenced in the the United States District Court for the Southern District of New York. Affected investors purchased or otherwise acquired certain Teladoc Health, Inc. securities between October 28, 2021 and April 27, 2022. Follow...

Teladoc Class Action: Levi & Korsinsky Reminds Teladoc Health, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2022 - TDOC

TDOC stock has been beaten down in 2022, and the fundamentals suggest more pain is likely after the company lowered its 2022 guidance. The post Teladoc Health Looks Like a Series of Red Flags appeared first on InvestorPlace.

Teladoc Health Looks Like a Series of Red Flags

Shareholders aren't taking the news of the Federal Reserve's big rate hike very well.

Why Teladoc Health Stock Slid Today

DraftKings

General Motors

UiPath

Roblox

Shopify

Block

These Cathie Wood Stocks offers phenomenal massive upside potential over the long-term for patient investors. The post 7 Cathie Wood Stocks That Could Make You Rich in the Long Term appeared first on InvestorPlace.

7 Cathie Wood Stocks That Could Make You Rich in the Long Term

Advanced Micro Devices

American Water Works

Campbell Soup

Intuitive Surgical

NextEra Energy

Procter & Gamble

Wondering which stocks to buy in a bear market? Here are the top picks to protect your portfolio as markets tumble.

The 7 Best Stocks to Buy in a Bear Market

LE AD PLAINTIFF DEADLINE IS AUGUST 5, 2022 NEW YORK , June 15, 2022 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC) in the United States District Court for the Southern District of New York on behalf of all those that purchased or otherwise acquired Teladoc securities between October 28, 2021 and April 27, 2022, both dates inclusive (the "Class Period"). All investors who purchased the shares of Teladoc Health, Inc. and incurred losses are advised to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774.

TELADOC HEALTH, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Teladoc Health, Inc.

New York, New York--(Newsfile Corp. - June 14, 2022) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Teladoc Health, Inc. (NYSE: TDOC).CLICK HERE FOR MORE DETAILS:https://claimyourloss.com/securities/teladoc-health-inc-loss-submission-form/?id=28595&from=5Aff

TDOC LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of TELADOC HEALTH, INC. Shareholders

New York, New York--(Newsfile Corp. - June 14, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Teladoc Health, Inc. (NYSE: TDOC) between October 28, 2021 and April 27, 2022, both dates inclusive (the "Class Period"). If you wish to serve as lead plaintiff, you must move the Court no later than August 5, 2022.SO WHAT:...

ROSEN, A Leading Law Firm, Encourages Teladoc Health, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - TDOC

New York, New York--(Newsfile Corp. - June 14, 2022) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Teladoc Health, Inc. (NYSE: TDOC).Shareholders who purchased shares of TDOC during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/teladoc-health-inc-loss-submission-form/?id=28579&from=5

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Teladoc Health, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 5, 2022 - (TDOC)

Teladoc Health's (TDOC) cash flows will likely gain from the growing number of visits and memberships.

Should You Hold On to Teladoc Health (TDOC) Stock for Now?

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming August 5, 2022 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC) securities between October 28, 2021 and April 27, 2022, inclusive (the “Class Period”). Investors suffering losses on their Teladoc investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Teladoc Health, Inc. (TDOC)

Los Angeles, California--(Newsfile Corp. - June 13, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Teladoc Health, Inc. ("Teladoc" or "the Company") (NYSE: TDOC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between October 28, 2021 and April 27, 2022, inclusive...

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Teladoc Health, Inc. with Losses of $1,000,000 to Contact the Firm

Investors should think twice before buying TDOC stock, considering the negative impact of the stay-at-home phase ending. The post Teladoc Can't Rely On Hype To Attract Investors appeared first on InvestorPlace.

Teladoc Can't Rely On Hype To Attract Investors

New York, New York--(Newsfile Corp. - June 12, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Teladoc Health, Inc. (NYSE: TDOC) between October 28, 2021 and April 27, 2022, both dates inclusive (the "Class Period"). If you wish to serve as lead plaintiff, you must move the Court no later than August 5, 2022.SO WHAT:...

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Teladoc Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TDOC

SAN DIEGO--(BUSINESS WIRE)---- $TDOC #TDOC--Robbins LLP Reminds Investors of Class Action Against Teladoc Health, Inc. (TDOC)

TDOC Shareholder Alert: Robbins LLP Reminds Investors of Class Action Against Teladoc Health, Inc. (TDOC)

NEW YORK , June 10, 2022 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Teladoc securities between October 28, 2021 and April 27, 2022, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/tdoc.

Bronstein, Gewirtz & Grossman, LLC Notifies Teladoc Health, Inc. (TDOC) Investors of Class Action and Encourages Investors to Contact the Firm

Los Angeles, California--(Newsfile Corp. - June 10, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Teladoc Health, Inc. ("Teladoc" or "the Company") (NYSE: TDOC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between October 28, 2021 and April 27, 2022, inclusive...

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Teladoc Health, Inc. with Losses of $1,000,000 to Contact the Firm

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 5, 2022 to file lead plaintiff applications in a securities class action lawsuit against Teladoc Health, Inc. (NYSE: TDOC), if they purchased the Company's securities between October 28, 2021 and April 27, 2022, inclusive (the “Class Period”). This action is pending in the United States District Court for the S

TELADOC HEALTH SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Teladoc Health, Inc. - TDOC

Beam Therapeutics

CRISPR Therapeutics

Exact Sciences

Intellia Therapeutics

Catherine Wood (Trades, Portfolio), the founder, chief investment officer and CEO of ARK Investment Management, has made a name for herself through investing in “disruptive innovation” stocks.

5 Health Care Stocks Cathie Wood Favors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming August 5, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC) securities between October 28, 2021 and April 27, 2022, inclusive (the “Class Period”). If you suffered a loss on your Teladoc investments or would like to inquire about potentially pursuing

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Teladoc Health, Inc. (TDOC)

Our theme of Out Of Favor Health Care Stocks includes healthcare and pharmaceutical names that are seeing a disconnect between their financial performance and recent stock price returns.

News for Teladoc Stock (TDOC)